Epidural Steroid Injections for Chronic Radiculopathy: Limited Short-Term Benefit Only
For chronic radiculopathy, epidural steroid injections provide modest short-term pain relief (up to 3 months) but no sustained long-term benefit, and should be offered only after careful patient counseling about their limited efficacy and potential serious harms. 1
Evidence-Based Recommendation
The most recent and authoritative guidance comes from the 2025 BMJ clinical practice guideline, which conducted a comprehensive network meta-analysis and found:
- Moderate certainty evidence demonstrates that epidural injections with local anesthetic plus steroids for chronic radicular spine pain probably have little to no effect on pain relief compared to sham procedures 1
- The guideline panel issued a strong recommendation AGAINST epidural injections for chronic radicular pain, stating "all or nearly all well-informed people would likely not want such interventions" 1
This represents a significant departure from older interventional pain society guidelines that favored these procedures.
Short-Term vs Long-Term Outcomes
What Actually Works (Marginally):
Short-term effects (≤3 months):
- Pain reduction: Mean difference of -7.55 points on 0-100 scale (below clinically meaningful threshold) 2
- Functional improvement: Standardized mean difference of -0.33 2
- Success rate difference of approximately 24% for pain reduction 3
- Number needed to treat: 4 for short-term pain relief 3
Long-term effects (≥6 months):
- No sustained benefit for pain (insufficient evidence) 3, 2
- Possible modest disability reduction (success rate difference 11.1%, NNT 9) but clinically questionable 3
- No reduction in long-term surgery risk 2
Critical Context:
The 2025 AAN systematic review 3 found "probably" reduced short-term pain and disability in radiculopathies, but acknowledged the benefits were below minimum clinically important difference thresholds. A high-quality 2011 RCT found no difference between epidural steroids, epidural saline, or subcutaneous sham injections at any time point up to 52 weeks 4.
Clinical Algorithm for Decision-Making
When to Consider (Rarely):
- Patient has failed conservative management (physical therapy, NSAIDs, neuropathic pain medications)
- Symptom duration < 6 months (chronic but not long-standing)
- MRI-confirmed nerve root compression correlating with clinical symptoms
- Patient accepts that benefit is modest, temporary, and may not exceed placebo
- Patient willing to accept risks including rare catastrophic complications
When to Avoid (Most Cases):
- Chronic axial (non-radicular) spine pain - no benefit 1
- Spinal stenosis - insufficient evidence of benefit 1, 2
- Symptoms > 12 months duration
- Patient seeking definitive or long-term solution
- Previous failed epidural injections
Serious Safety Concerns
The FDA Adverse Event Reporting System documented 90 serious adverse events between 1997-2014 following epidural corticosteroid injections, including 1:
- Death
- Spinal cord infarction
- Paraplegia/quadriplegia
- Cortical blindness
- Stroke and seizures
Common moderate harms (from trials) 1:
- Prolonged pain/stiffness >48 hours: 8.6%
- Temporary altered consciousness: 2.1%
- Dural puncture: 1.4%
- Deep infection: 0.7%
Practical Realities
Burden to patients:
- Requires travel to specialized facility
- Fluoroscopic guidance necessary for any potential benefit
- If perceived effective, injections repeated every 2-12 weeks indefinitely 1
- Significant out-of-pocket costs in many healthcare systems
- No curative effect - purely symptomatic and temporary
Reconciling Contradictory Guidelines
There is stark disagreement between interventional pain societies and evidence-based medicine groups:
Pro-injection (older guidelines):
- 2021 ASIPP: Strong recommendation FOR epidural steroids in radiculopathy 1
- 2022 ASPN: Strong recommendation FOR epidural injections 1
Against injection (recent evidence-based guidelines):
- 2025 BMJ: Strong recommendation AGAINST 1
- 2020 NICE: Do not offer spinal injections 1
- 2021 ACOEM: Recommended against for most indications 5
The 2025 BMJ guideline 1 explicitly addressed this controversy, noting that interventional society guidelines are typically "consensus-based" rather than evidence-based, rarely include patient partners, and often authored by clinicians with financial interests in performing these procedures. A 2023 analysis found positive results were 3 times more likely when reviews were authored by interventionalists versus non-interventionalists 1.
Alternative Approach
For acute-to-subacute radiculopathy (<12 weeks): Consider time-limited trial of neuropathic pain medications (gabapentin/pregabalin) plus physical therapy. Natural history favors improvement in 6-12 weeks.
For chronic radiculopathy (>12 weeks): Epidural injections offer minimal benefit. Focus on functional restoration, pain psychology approaches, and surgical evaluation if neurological deficits present or quality of life severely impaired.
Recent data on oral steroids: A 2026 systematic review found oral corticosteroids may provide modest functional benefit with fewer risks than epidural administration, though evidence remains limited 6.
Bottom Line
The highest quality, most recent evidence demonstrates that epidural steroid injections for chronic radiculopathy provide at best small, temporary improvements that do not meet clinically meaningful thresholds and carry real risks of catastrophic harm. The 2025 BMJ guideline's strong recommendation against these procedures should guide practice 1, particularly given the lack of long-term benefit and the availability of safer alternatives.